Navigation Links
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Date:10/6/2008

Creates a Global Leader in Oncology Biopharmaceuticals Boosts Oncology Pipeline With Up to Three Promising Targeted Therapies in

Phase III in 2009

INDIANAPOLIS and NEW YORK, Oct. 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and ImClone Systems Inc. (Nasdaq: IMCL) today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion. The offer represents a premium of 51 percent to ImClone's closing stock price on July 30, 2008, the day before an acquisition offer for ImClone was made public. ImClone's board recommends that ImClone's shareholders tender their shares in the tender offer. Additionally, certain entities associated with ImClone's chairman, Carl C. Icahn, holding approximately 14 percent of ImClone's outstanding common stock, have agreed to tender their shares in the tender offer.

This strategic combination will create one of the leading oncology franchises in the biopharmaceutical industry, offering both targeted therapies and oncolytic agents along with a pipeline spanning all phases of clinical development. The combined oncology portfolio will target a broader array of solid tumor types including lung, breast, ovarian, colorectal, head and neck, and pancreatic, positioning Lilly to pursue treatments of multiple cancers. Combining with ImClone will further strengthen Lilly's growin
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
2. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
3. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
4. Amylin and Lilly Set Date and Time for Conference Call
5. Lilly Announces Completion of SGX Acquisition
6. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
7. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
8. Lilly Reports Solid Second-Quarter Results
9. Lilly to Acquire SGX Pharmaceuticals
10. Lillys Connelly Appointed to the Presidents Commission on White House Fellowships
11. Lilly Employees from Nearly 50 Nations Participate in Companys First-Ever Global Day of Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
(Date:8/28/2014)... 27, 2014 Scientists, researchers, and technologists ... SPIE Laser Damage 2014 symposium. Marking its 46th ... lasers will run 14-17 September. The event is sponsored ... photonics . , The premier conference for basic and ... to optical materials will engage researchers and engineers from ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Earlier this ... University in partnership with the U.S. Air Force ... biofuel. The results indicated that this type of fuel ... feedstock and will be important to America’s Eco friendly ... now has a mandate to become independent of foreign ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... - Non-responder and Null Responder HCV patients -- ... -BRISBANE, Calif., April 21 InterMune, Inc. (Nasdaq: ... innovative clinical study of protease inhibitor ITMN-191 (R7227) ... referred to as the INFORM-1 study, has been ...
... Response Data from Dose-Escalation Study Presented at , ... 2009 -SOUTH SAN FRANCISCO, Calif. and DENVER, April ... PARD ), a biopharmaceutical company focused on oncology, ... a Phase 1 dose-escalation study of picoplatin in ...
... Data on novel pro-apoptotic agent presented at the ... Cancer Research -- University of Pennsylvania ... lines, highlighting AT-101,s inhibition of Mcl-1, also presented ... announced today that the results of preclinical studies ...
Cached Biology Technology:INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 2INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 3INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 4INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 5Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 5Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models 2Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models 3
(Date:8/28/2014)... Mayo Clinic researcher and his collaborators have developed an ... the process of re-engineering cells for biomedical investigation. CellNet ... methods to aid stem cell engineering. Details of CellNet ... in two back-to-back papers in the journal Cell ... of uses for all types of cell-based investigations and ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced ... of America,s 27th Annual Mouse Molecular Genetics Conference ... Pacific Grove, California. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the Genetics ...
(Date:8/28/2014)... N.C. -- Scientists have identified the developmental on-off switch ... that produce more than two-thirds of the world,s naturally ... be to see whether it is possible to manipulate ... , The study, appearing August 28 in ... small molecule called cyclic-di-GMP and a larger protein called ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... State University researchers have uncovered a pattern of distrust ... hospitals and midwives who are transporting their home-birth clients ... State University assistant professor Melissa Cheyney and doctoral student ... between physicians and midwives that is reflective of discord ...
... Phase I SBIR grant of $1,296,403 from the ... "Differential Phase Contrast Imaging" using the unique x-ray ... The grant will allow Lyncean to continue ... and its applications to new methods of imaging ...
... built a new tissue scaffold that can stimulate bone ... other joints. The scaffold could offer a potential ... such as arthritis, says Lorna Gibson, the Matoula S. ... of the research team with Professor William Bonfield of ...
Cached Biology News:Study reveals conflict between doctors, midwives over homebirth 2Study reveals conflict between doctors, midwives over homebirth 3Lyncean Technologies Inc. receives $1.2 M from NCRR to develop new imaging technique 2MIT: New tissue scaffold regrows cartilage and bone 2
... Conjugate Stabilizer is an aqueous solution that ... non-toxic stabilizing chemicals in a MOPS buffer ... This product contains a combination of ... Proclin 300 (Rohm and Haas Company) as ...
Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
Request Info...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: